4basebio (4BB) Share Price, News & Analysis

Company Overview

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.

Key Stats

• Today's Range: 986.77 to 1,080
• 50-Day Range: 1,000 to 1,204
• 52-Week Range: 986.77 to 1,820
• Volume: 4,674 shs
• Average Volume: 956 shs
• Market Capitalization: £128.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 1,600
• Consensus Rating: Buy

4BB Stock Analysis - Frequently Asked Questions

How have 4BB shares performed this year?

4basebio's stock was trading at GBX 1,210 at the beginning of 2025. Since then, 4BB shares have decreased by 17.4% and is now trading at GBX 1,000.
View the best growth stocks for 2025 here.

How were 4basebio's earnings last quarter?

4basebio PLC (LON:4BB) released its earnings results on Tuesday, May, 27th. The company reported ($0.94) earnings per share for the quarter.

How do I buy shares of 4basebio?

Shares of 4BB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of 4basebio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 4basebio investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX).

Company Calendar

• Last Earnings: 5/27/2025
• Today: 6/14/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:4BB
• CIK: N/A
• Web: www.4basebio.com
• Phone: 44 1223 967 943
• Fax: N/A
• Employees: 101
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 1,600
• High Stock Price Target: GBX 1,600
• Low Stock Price Target: GBX 1,600
• Potential Upside/Downside: +60.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£9.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -231.29%
• Return on Assets: -54.30%

Debt

• Debt-to-Equity Ratio: 201.47
• Current Ratio: 2.73
• Quick Ratio: 3.52

Sales & Book Value

• Annual Sales: £311 thousand
• Price / Sales: 411.90
• Cash Flow: GBX 62.19 per share
• Price / Cash Flow: 16.08
• Book Value: GBX (41) per share
• Price / Book: -24.39

Miscellaneous

• Outstanding Shares: 12,810,000
• Free Float: N/A
• Market Cap: £128.10 million
• Optionable: Not Optionable
• Beta: 1.09